Tarceva lung cancer targeted drug in India 13621079267 Tarceva price in India

::(,,) / ,::(,,) :> Shanghai Roche Pharmaceutical Co., Ltd. announced yesterday that its subsidiary will treat:,(,,) >:, >non-small cell lung cancer
The price of targeted drug Tarceva will be reduced by %. In the national drug price negotiations launched for the first time this year, Tarceva was ultimately not included in the price reduction catalog announced in March, with a price reduction range of % and %.
::(,,) / ,::(,,) :> Shanghai Roche Pharmaceutical Co., Ltd. announced yesterday that it will take the initiative to sell its targeted drugs for the treatment of non-small cell lung cancer:,(,,) >:, >[Erlotinib (Tarceva)]
The price has been reduced by %. After the price reduction, patients receiving this drug can save more than 10,000 yuan in drug costs every year. It is worth noting that this year, the country launched a price reduction catalog negotiation mechanism for new anti-cancer drugs for the first time. Roche’s Tarceva also participated in the price negotiations, but was ultimately not included in the price reduction catalog announced last month.
::(,,) / ,::(,,) :>:, > Event
::(,,) / ,::(,,) :>:, > Troquet The price reduction can save patients more than 10,000 yuan per year
::(,,) / ,::(,,) :> Roche released a statement to the media yesterday about the price adjustment of Tarceva, saying that Roche has been actively Support and cooperate with the country's efforts to deepen the reform of the medical and health system, reduce the drug burden of patients, improve drug accessibility and affordability, promote the linkage of medical care, medical insurance, and medicine, and guide the healthy development of the pharmaceutical industry. As one of the cornerstone drugs in the field of lung cancer treatment, Tarceva has benefited more than 10,000 lung cancer patients since its launch in China, significantly extending the survival period of lung cancer patients and effectively improving their quality of life. Shanghai Roche Pharmaceutical Co., Ltd. recently decided to proactively adjust the price of Tarceva by 0% to benefit more Chinese lung cancer patients. The exact price reduction may vary slightly due to differences in base prices in various locations.
::(,,) / ,::(,,) :> It is understood that the current selling price of Tarceva is about RMB () per box of tablets. After the price reduction, it can provide 1,000 yuan per box of tablets for patients treated with the drug every year. Save more than 10,000 yuan in medication costs.
::(,,) / ,::(,,) :>:, >
::(,,) / ,::(,,) :> According to the collection of the National Cancer Registration Center Data show that lung cancer is still the malignant tumor with the highest morbidity and mortality in my country, and there are more than 10,000 new lung cancer patients in the country every year. Non-small cell lung cancer accounts for approximately % of all lung cancers. It is understood that Roche Pharmaceuticals, the manufacturer of the well-known non-small cell lung cancer treatment drug Tarceva, also actively participated in price negotiations at the time, but ultimately failed to appear in the drug price reduction list, thus triggering speculation from all parties.
::(,,) / ,::(,,) :> Regarding the national negotiation incident this month, Roche said in its response that there were previous media reports that Roche had withdrawn from national negotiations, and there were some misunderstandings in this. In fact, Roche actively participated in the first round of pilot negotiations on drug prices and received approval from relevant departments.
::(,,) / ,::(,,) :> According to insiders, after the country determined the "choose three to enter two" competition rules, Roche was very sincere and was the first to express it in the first round of negotiations. However, Tarceva failed to gain an advantage in the following rounds of negotiations. In fact, Tarceva's reduction was similar to the final announced result. & the person familiar with the matter said.
::(,,) / ,::(,,) :>:, >